Masimo - MASI Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MASI shares.
View MASI analyst ratings or view top-rated stocks.

7 brokerages have issued 12-month price objectives for Masimo's stock. Their MASI share price forecasts range from $135.00 to $295.00. On average, they anticipate the company's stock price to reach $190.29 in the next year. This suggests a possible upside of 35.3% from the stock's current price.
View analysts price targets for MASI or view top-rated stocks among Wall Street analysts.

Masimo's stock was trading at $292.78 at the beginning of the year. Since then, MASI shares have decreased by 52.0% and is now trading at $140.65.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our MASI earnings forecast.

Masimo Co. (NASDAQ:MASI) issued its quarterly earnings data on Monday, October, 25th. The medical equipment provider reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.03. The medical equipment provider had revenue of $307.40 million for the quarter, compared to analysts' expectations of $295.79 million. Masimo had a trailing twelve-month return on equity of 18.04% and a net margin of 9.78%. The business's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.80 earnings per share.

Masimo issued an update on its fourth quarter earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of $1.11-1.22 for the period, compared to the consensus earnings per share estimate of $1.25. The company issued revenue guidance of $581-611 million, compared to the consensus revenue estimate of $617.17 million.

136 employees have rated Masimo Chief Executive Officer Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), Trade Desk (TTD), Walt Disney (DIS) and Twilio (TWLO).

Masimo trades on the NASDAQ under the ticker symbol "MASI."

Masimo's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.30%), Politan Capital Management LP (8.84%), Vanguard Group Inc. (8.80%), State Street Corp (3.15%), RTW Investments LP (2.74%) and Liontrust Investment Partners LLP (2.17%). Insiders that own company stock include Adam Mikkelson, Anand Sampath, Bilal Muhsin, Craig B Reynolds, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Tao Levy, Thomas Samuel Mcclenahan and Yongsam Lee.
View institutional ownership trends.

Shares of MASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MASI stock can currently be purchased for approximately $140.65.

Masimo (NASDAQ:MASI) has a market capitalization of $7.39 billion and generates $1.24 billion in revenue each year. The medical equipment provider earns $229.65 million in net income (profit) each year or $3.02 on an earnings per share basis.

The company employs 6,200 workers across the globe.

Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The official website for the company is www.masimo.com. The medical equipment provider can be reached via phone at (949) 297-7000, via email at ekammerman@masimo.com, or via fax at 949-297-7001.